Lysergide tartrate (LSD) · DT120

Small molecule

Also known as DT120

Partialsignal

Evidence outlook · lead readout

NCT06809595 · Generalized Anxiety Disorder

The completed lead evidence is positive, with design limits that temper confidence; the rationale below says which.

NCT06809595: Panorama was a randomized, triple-masked, placebo-controlled Phase 3 in 245 participants in generalized anxiety disorder. Its primary endpoint, HAM-A change, is a validated clinical scale and was met (p<0.0001) according to the company's topline release. The sources read give no power calculation, so the grade is moderate.

Also in development:Major Depressive Disorder · Phase 3Attention Deficit Hyperactivity Disorder · Phase 2

Company guidance: regulatory filing expected first half of 2027 (Definium Therapeutics, 9 Nov 2026). “On track for DT120 ODT NDA filing in first half of 2027” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (4)
Generalized Anxiety Disorder
Major Depressive Disorder
Phase 2 (3)
Attention Deficit Hyperactivity Disorder
NCT05200936 · Definium Therapeutics US, Inc.
2021-12-17 – 2023-12-04 · ADHD, Attention Deficit Disorder
What this study did
Major Depressive Disorder
NCT03866252 · University Hospital, Basel, Switzerland
2019-11-01 – 2022-12-01 · Major Depressive Disorder
What this study did
Other / comorbidity
Phase 1 (1)
Other / comorbidity
NCT04865653 · University Hospital, Basel, Switzerland
2022-03-17 – 2023-10-11 · Healthy
What this study did

Competitive landscape

7 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Attention Deficit Hyperactivity Disorder: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Lysergide Tartrate (LSD) (DT120): this drugPhase 2Small molecule5-HT2A receptornot yet gradedNo reviewed efficacy summary in this indication
Centanafadine (Simtriyo)ApprovedSmall moleculeSerotonin/norepinephrine/dopamine transporterReliable signal
NCT05257265: ADHD-RS-5 change at week 6: -18.50 [0.93] centanafadine 328.8 mg vs -14.15 [0.93] placebo (p = .0006); 164.4 mg did not meet the primary endpoint
Viloxazine (Qelbree)ApprovedSmall moleculenorepinephrine transporterReliable signal
NCT04016779: Efficacy of SPN-812 on Symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) as Assessed by the Adult ADHD Investigator Symptom Rating Scale (AISRS) Total Score (Baseline and Week 6): Placebo -11.7 units on a scale (Standard Error 0.9) | SPN-812 -15.5 units on a scale (Standard Error 0.91)
NCT03247543: Efficacy of SPN-812 Assessed by Attention-Deficit/Hyperactivity Disorder Rating Scale, 5th Edition (ADHD-RS-5) (Baseline and Week 8 (End of Study)): Placebo -11.7 units on a scale (Standard Error 1.48) | 200mg SPN-812 -17.6 units on a scale (Standard Error 1.43) | 400mg SPN-812 -17.5 units on a scale (Standard Error 1.52)
Solriamfetol (Sunosi)Phase 3Small moleculeDopamine/norepinephrine transporternot yet gradedNo reviewed efficacy summary in this indication
PDC-1421Phase 2BotanicalPolygalae radix extract (active components: tenuifolin, polygalasaponins, etc.)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow DT120 (Lysergide tartrate (LSD)) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
September 2027 (1)
Phase 3Major Depressive DisorderRecruiting
Est. primary completion 2027-09 · NCT07592689 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

14 September 2026Topline resultPhase 3 Panorama (NCT06809595) met its primary endpoint in GAD
Definium Therapeutics · Source ↗
12 August 2026Topline resultPhase 3 Voyage (NCT06741228) reported positive topline results in GAD
Definium Therapeutics · Source ↗
22 June 2026Topline resultEmerge Phase 3 meets primary endpoint
Definium Therapeutics · Source ↗